investment

The company will use the funds to expand its US-based business and to commercialize its data visualization platform.

The company will use the funds to increase its overseas footprint, and to optimize its genetic testing procedures and protocols, among other improvements.

The British CRISPR software developer is turning to investment platform SyndicateRoom as it looks to commercialize its products and expand into the US.

Both deals should advance Ginkgo's custom microbe business as it expands into consumer goods markets such as cosmetics, nutrition, and food.

The yet-to-be-named entity will draw on the partners' respective resources in synthetic biology and plant and agricultural products.

The newly announced Genomics Aotearoa collaborative platform seeks to accelerate adoption and application of genomics technology across multiple disciplines.

The newly announced Genomics Aotearoa collaborative platform seeks to accelerate adoption and application of genomics technology across multiple disciplines.

Asking for the Data

Biotech investors are learning from their mistakes following the Theranos fiasco, according to Wired.

Kailos said it plans to use the investment in a partnership with In-Q-Tel to develop its technology for the intelligence community.

SOL will help Personal Genomics to further develop its research projects and implement its new facility dedicated to DNA sequencing.

The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.

Pages

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.